CRO Services
Participate In a Study
About Us
Careers
Contact
FR
CRO Services
Participate In a Study
About Us
Careers
Contact
FR
Test
Post navigation
Secukinumab Sustains Good Efficacy and Favourable Safety in Moderate to Severe Psoriasis up to 3 Years of Treatment: Results from A Double-Blind Extension Study
Increased frequencies of basophils, type 2 innate lymphoid cells and Th2 cells in skin of patients with atopic dermatitis but not psoriasis
